• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Serve You Rx Adds Two New Biosimilars to its Formulary

by Fred Pennic 06/05/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Serve You Rx announced today the inclusion of two newly approved biosimilars to Stelara® (ustekinumab) – Otulfi™ (ustekinumab-aauz) and Yesintek™ (ustekinumab-face) – to its Biosimilar Advantage Formulary. This move is set to deliver substantial savings for self-funded employers and health-plan sponsors while maintaining therapeutic benefits for patients with conditions like Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.

– Serve You Rx, a full-service pharmacy benefit manager (PBM), is expanding its cost-saving solutions by incorporating Otulfi™ and Yesintek™, biosimilars to the widely used specialty drug Stelara®.

Significant Cost Reduction Opportunities

“The numbers tell the story here,” stated Justin Jasniewski, CEO of Serve You Rx. “With savings of up to 96% compared to as much as $152,000 annually for Stelara, these biosimilars represent a significant opportunity for our clients to manage healthcare costs while maintaining quality care for their members.”

This initiative is a collaborative effort with Mark Cuban Cost Plus Drugs and Waltz Health, aimed at improving access to high-cost specialty medications through transparent pricing and simplified distribution channels.

Collaborative Approach to Enhance Access and Affordability

“Making biosimilars like Otulfi available through Cost Plus Drugs is another step toward breaking down barriers to access,” said Dr. Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. “By working with Serve You Rx, we’re helping more patients and health plans avoid the inflated costs that have defined the specialty drug market for too long.”

Details of the distribution include:

  • Otulfi™: To be dispensed exclusively through Mark Cuban Cost Plus Drugs via the Waltz Health specialty pharmacy network. Members are projected to save more than 96% annually compared to Stelara®.
  • Yesintek™: Will be available through Serve You Rx’s specialty pharmacy network, powered by Waltz Health. It is expected to deliver over 90% annualized savings for plan sponsors while treating the same conditions as Stelara®.

Both medications will be supported by robust copay assistance programs to ensure patient access without imposing financial barriers.

Waltz Health offers a comprehensive solution that includes a specialty pharmacy network competing on price and service, a guided patient experience, and a flexible service model designed to balance cost and patient outcomes.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

 Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

CMS Finalizes New Interoperability and Prior Authorization Rule

CMS Proposes 2026 Physician Fee Schedule Rule: Boosting Primary Care, Cutting Waste, and Modernizing Payments

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

New Strategies Needed: No Surprises Act and the Challenges for Payors with Provider Data Inaccuracies

Samsung Acquires Xealth to Accelerate Connected Care Vision

Samsung Acquires Xealth to Accelerate Connected Care Vision

AI Dominates Digital Health Investment in First Half of 2025

Rock Health Report: AI Dominates Digital Health Investment in First Half of 2025

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |